Advanced in Philadelphia-Negative Chronic Myeloid Leukemia

Dr. Daniel N. Egan

Hematology Oncology
1221 Madison Street, Floor 10, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
1221 Madison Street, Floor 10, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Egan is a Hematologist Oncology provider in Seattle, Washington. Dr. Egan is rated as an Advanced provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Egan is currently accepting new patients.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Swedish Edmonds Hospital
Swedish Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

1221 Madison Street, Floor 10, Seattle, WA 98104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML
Enrollment Status: Terminated
Publish Date: July 14, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Aldesleukin, Cyclophosphamide, Fludarabine, WT1-Sensitized Allogeneic T Lymphocytes
Study Phase: Phase 1/Phase 2
Phase I/II Study of Autologous (Central Memory/Naïve) CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of AML
Phase I/II Study of Autologous (Central Memory/Naïve) CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of AML
Enrollment Status: Terminated
Publish Date: October 29, 2021
Intervention Type: Biological, Other
Study Drugs: Aldesleukin, WT1-Sensitized Autologous T Lymphocytes
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

14 Total Publications

A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.
Journal: Nature communications
Published: March 31, 2025
Similar Doctors
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Vivian G. Oehler
Oncology | Hematology Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Vivian G. Oehler
Oncology | Hematology Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (2.8 miles away)
206-598-4333
Languages Spoken:
English, German, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Vivian Oehler is an Oncologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Oehler is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Leukemia, Philadelphia-Negative Chronic Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Oehler is currently accepting new patients.

Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Raya Mawad
Hematology Oncology | Hematology | Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Raya Mawad
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.2 miles away)
206-288-1000
Languages Spoken:
English, Arabic, Danish, French, Romanian
See accepted insurances
Accepting New Patients
Offers Telehealth

Raya Mawad is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Mawad is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Philadelphia-Negative Chronic Myeloid Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mawad is currently accepting new patients.

Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Laura S. Connelly-Smith
Hematology | Oncology | Hematology Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Laura S. Connelly-Smith
Hematology | Oncology | Hematology Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.2 miles away)
206-288-1000
Languages Spoken:
English, Farsi, Portuguese, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Connelly-Smith is a Hematologist and an Oncologist in Seattle, Washington. Dr. Connelly-Smith is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Transplant. Dr. Connelly-Smith is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Egan's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile